Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin tregopil - Biocon

Drug Profile

Insulin tregopil - Biocon

Alternative Names: GW 843362; Hexyl Insulin M2; Hexyl insulin monoconjugate 2; HIM2; IN-105; NIN-058; Oral prandial insulin - Biocon

Latest Information Update: 15 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nobex Corporation
  • Developer Biocon; Bristol-Myers Squibb
  • Class Antihyperglycaemics; Hormones; Insulins; Peptides
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 2 diabetes mellitus
  • Phase II Type 1 diabetes mellitus

Most Recent Events

  • 06 Feb 2019 Biocon completes a phase II/III trial in Type 2 diabetes mellitus in India (NCT03430856)
  • 26 Dec 2017 Biocon initiates enrolment in a phase II/III trial for Type-2 diabetes mellitus in India (PO) (NCT03430856)
  • 06 Sep 2017 Biocon and JDRF agree to co-develop Insulin tregopil for Type-1-diabetes (http://www.biocon.com/docs/Biocon_Annual_Report_2017.pdf)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top